Open Labs Key to Cracking Toughest Health Problems?
The Policy Innovations website noted that there’s now a growing consensus that the open innovation approach is key to tackling disease in the developing world. GlaxoSmithKline’s (GSK) Open Lab has turned the traditional research and development (R&D) model of closed innovation—of companies working behind closed doors and guarding the findings of their research—on its head. Here, external researchers from leading research institutions around the world are invited to work with GSK scientists on their own projects, accessing GSK drug discovery and pre-clinical expertise.
Click here to read the full article.